{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:46:03Z","timestamp":1788824763064,"version":"build-2803163510"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>\n                    The role of fibroblast activation protein inhibitor (FAPI) as a novel radiopharmaceutical in the field of cancer diagnosis and treatment (theranostic) is still under investigation. We present 2 patients of differentiated thyroid cancer with thyroglobulin elevation and negative iodine scintigraphy (TENIS syndrome) who underwent\n                    <jats:sup>99<\/jats:sup>\n                    mTc-OCTREOTIDE scan and 99mTc-FAPI SPECT\/CT to evaluate possible sites for metastasis.\n                    <jats:sup>99<\/jats:sup>\n                    mTc-OCTREOTIDE scan showed no remarkable uptake in these patients. On the other hand, foci of metastatic disease were found, with intense\n                    <jats:sup>99<\/jats:sup>\n                    mTc-FAPI-46 uptake. Malignant FAPI uptake was evident in the lungs, liver, adrenal, and abdominal lymph nodes in a patient and in the lungs of another one. Due to proper uptake in diagnostic scans, these patients were recognized as a suitable candidate for treatment with\n                    <jats:sup>177<\/jats:sup>\n                    Lu-FAPI-46.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000005817","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T16:17:41Z","timestamp":1743697061000},"page":"e290-e291","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Significant 99mTc-FAPI-46 Uptake in 2 Cases of TENIS Syndrome With Negative Tc-OCTREOTIDE Scan, a New Hope in Theranostic Applications"],"prefix":"10.1097","volume":"50","author":[{"given":"Mitra","family":"Ghahraman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Aryana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Rasoul","family":"Zakavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farivash","family":"Karamian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atena","family":"Aghaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"R1-20250403","first-page":"269","article-title":"Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: a case report of significant response to lu177 DOTA-TATE treatment","volume":"66","author":"Ataei-Nakhaei","year":"2022","journal-title":"Arch Endocrinol Metab"},{"key":"R2-20250403","first-page":"116","article-title":"Use of 177Lu-dotatate in the treatment of iodine refractory thyroid carcinomas","volume":"36","author":"Oliv\u00e1n-Sasot","year":"2017","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"R3-20250403","doi-asserted-by":"crossref","first-page":"896287","DOI":"10.3389\/fendo.2022.896287","article-title":"Peptide receptor radionuclide therapy in thyroid cancer","volume":"13","author":"Gubbi","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R4-20250403","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s41181-024-00264-0","article-title":"99mTc-labeled FAPI compounds for cancer and inflammation: from radiochemistry to the first clinical applications","volume":"9","author":"Boschi","year":"2024","journal-title":"EJNMMI Radiopharm Chem"},{"key":"R5-20250403","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00259-022-06067-2","article-title":"[18F]FAPI-42 PET\/CT in differentiated thyroid cancer: diagnostic performance, uptake values, and comparison with 2-[18F]FDG PET\/CT","volume":"50","author":"Mu","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R6-20250403","doi-asserted-by":"crossref","first-page":"e220749","DOI":"10.1148\/radiol.220749","article-title":"FAPI PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease","volume":"306","author":"Mori","year":"2023","journal-title":"Radiology"},{"key":"R7-20250403","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1158\/1078-0432.CCR-23-1983","article-title":"Fibroblast activation protein-targeted radioligand therapy with 177Lu-EB-FAPI for metastatic radioiodine-refractory thyroid cancer: first-in-human, dose-escalation study","volume":"29","author":"Fu","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R8-20250403","doi-asserted-by":"crossref","first-page":"1381863","DOI":"10.3389\/fmed.2024.1381863","article-title":"Diagnostic yield of FAP-guided positron emission tomography in thyroid cancer: a systematic review","volume":"11","author":"Rizzo","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"R9-20250403","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3390\/cancers16040839","article-title":"FAPi-based agents in thyroid cancer: a new step towards diagnosis and therapy? A systematic review of the literature","volume":"16","author":"Guglielmo","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R10-20250403","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-023-06452-5","article-title":"PET\/CT imaging with radiolabeled FAPI: new opportunities for diagnosis and treatment of thyroid cancer","volume":"51","author":"Piscopo","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R11-20250403","doi-asserted-by":"crossref","first-page":"924841","DOI":"10.3389\/fendo.2022.924841","article-title":"Theranostic options for radioiodine-refractory differentiated thyroid carcinoma: recent advances, challenges, and road ahead","volume":"13","author":"Satapathy","year":"2022","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000005817","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:40:51Z","timestamp":1786034451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000005817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005817","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"2024-08-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}